EDNRB (Endothelin Receptor Type B)

CCL2 exhibited significant correlations with M1 macrophages, M2 macrophages, Neutrophils, T cells CD4 memory resting and Plasma cells. These findings elucidate the causal association between H. pylori UREA antibody levels and DLBCL, while underscoring the potential for targeted therapy in H. pylori-positive patients diagnosed with DLBCL.

Additionally, immune cell infiltration analysis using CIBERSORT revealed a higher proportion of macrophages in both cancer types compared to non-tumor tissues. In conclusion, our study suggests that shared genetic alterations, regulated by specific TFs and miRNAs, alongside an altered immune microenvironment and CXCL12-mediated inositol phosphate metabolism likely driven by intermediate monocytes, contribute to the development of SPLC following laryngeal cancer.

Ednrb functions as a key mediator in TXA-induced PTOA progression. The binding of TXA to ETB activates the relaxin and ET-1/ETB pathways, thereby promoting cartilage degradation and inflammation. Targeting Ednrb may represent a promising therapeutic strategy for preventing TXA-associated PTOA.

In vitro validation demonstrated that albuterol sulfate (salbutamol) exhibited moderate cytotoxicity toward A549 lung cancer cells (IC₅₀ = 150 µg/mL) with markedly reduced toxicity in WI38 normal lung fibroblasts, supporting its selective anticancer activity with minimal effects on normal human cells. Overall, this study highlights the central role of collagen dysregulation in linking CHP and LC, and demonstrates how integrating in silico, in vitro, and clinical analyses, together with molecular docking approaches, can uncover novel therapeutic insights for fibrotic and oncogenic pathologies.

Our findings reveal that endothelial Netrin-4 is a dual regulator of OPCs dynamics in PWMI, driving proliferation via ET-1 while impairing differentiation. Targeting the Netrin-4/ET-1 axis restores OPCs maturation, offering a potential strategy to mitigate myelination deficits in PWMI.

Additionally, high expressions of the 10-NMRGs were noted in the mesenchymal GBM subtype. Collectively, our analysis highlights the potential use of the 10-NMRG signature to stratify the high-risk GBM group with a strong association of immunomodulation and tumour-associated hallmarks that can contribute to the poor survival outcomes.

Nonetheless, CSL therapy notably reversed these pathological changes via upregulating SIRT1/FOXO3a and endothelin pathways while reducing cardiac inflammation, apoptosis and cardiac function markers. Our results are validated through in-silico which showed that CSL showed high binding affinity with key regulatory pathways.

Elevated SLC38A4 expression is correlated with a favorable prognosis in CRLM, likely through mechanisms involving metabolic reprogramming and immune infiltration. Thus, SLC38A4 may serve as both a prognostic biomarker and a potential biomarker for future therapeutic investigation, offering new precision medicine options for CRLM patients.

Notably, ADAMDEC1 expression in CAFs was significantly correlated with T-cell infiltration within the tumor microenvironment. In conclusion, our investigation elucidates the characteristics and clinical relevance of Tr-CAFs in colorectal cancer, suggesting novel avenues for targeted anti-CAF therapy.

We established an innovative signature associated with calcium signaling that serves as a reliable prognostic indicator for GC. Our findings may pave the way for enhanced diagnostic and therapeutic approaches in the context of GC.

Our findings demonstrate that CAV1 exerts its anti-tumor effects, at least in part, by inhibiting EGFR degradation and modulating the AKT/STAT3 pathway, as well as enhancing the Bax/Caspase-3/Bcl-2 signaling pathway in LUAD cells. These results suggest that targeting CAV1 may represent a promising therapeutic strategy for the treatment of LUAD patients.

Pharmacological inhibition of BMI1 using PTC-209 significantly attenuated cell proliferation, migration, and cell cycle progression in both SH-SY5Y neuroblastoma cells and primary enteric neural crest cells (ENCCs), whereas BMI1 overexpression produced the opposite effects...Molecular level probing revealed that BMI1 binds to the promoter region of Axin2, an inhibitor of the Wnt signaling pathway, and inhibited Axin2 transcription by increasing H2AK119ub and decreasing H3K4me3 in the Axin2 promoter, thereby hindering Wnt signaling. This study revealed that the BMI1/Axin2/Wnt axis may play an important role in the pathogenesis of HSCR.